Prasad Rajendra, Gupta Nikhil, Banka Amitabh
Department of Pulmonary Medicine, ERA'S Medical College and Hospital, Lucknow, Uttar Pradesh, India.
Department of Internal Medicine, ERA'S Medical College and Hospital, Lucknow, Uttar Pradesh, India.
Lung India. 2018 Jan-Feb;35(1):78-81. doi: 10.4103/lungindia.lungindia_98_17.
Multidrug-resistant tuberculosis (MDR-TB)/rifampicin-resistant TB (RR-TB) is human-made problem and emerging due to poor management of TB and is a threat to control of TB. Early suspicion and diagnosis are important. Culture and drug susceptibility testing are gold standards, but newer molecular methods help in rapid diagnosis. Once diagnosed, prompt treatment should be started, preferably under direct observation. Treatment can be standardized or individualized. Conventional regimen takes up to 24 months but recently shorter regimen of up to 12 months was introduced in specific subset of MDR-TB/RR-TB patients. Management of MDR-TB/RR-TB is complicated, costlier, and challenging and is a concern for human health worldwide. It must be emphasized that optimal treatment of MDR-TB/RR-TB alone is not sufficient. Efforts must be made to ensure effective use of first- and second-line anti-TB drugs.
耐多药结核病（MDR-TB）/利福平耐药结核病（RR-TB）是一个人为造成的问题，由于结核病管理不善而出现，对结核病控制构成威胁。早期怀疑和诊断很重要。培养和药敏试验是金标准，但更新的分子方法有助于快速诊断。一旦确诊，应立即开始治疗，最好在直接观察下进行。治疗可以标准化或个体化。传统疗程长达24个月，但最近在特定的耐多药结核病/利福平耐药结核病患者亚组中引入了长达12个月的较短疗程。耐多药结核病/利福平耐药结核病的管理复杂、成本高且具有挑战性，是全球人类健康关注的问题。必须强调的是，仅对耐多药结核病/利福平耐药结核病进行最佳治疗是不够的。必须努力确保一线和二线抗结核药物的有效使用。
